While MCD inhibitors have not been tested in patients with heart failure, preclinical studies have demonstrated that inhibition of MCD causes a decrease in fatty acid β-oxidation, increases glucose oxidation, and enhances insulin sensitivity [177,178,179]. This evidence concerns the gene INS and heart failure.